Peer-reviewed veterinary case report
Safety and immune effects of one anti-IgE antibody shot in dogs
By Hammerberg, Bruce & Eguiluz-Hernandez, Sitka·Published in Veterinary dermatology·2017·Department of Population Health and Pathobiology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one time injection in four dogs.
- Species:
- dog
Plain-English summary
A group of four healthy dogs received a single injection of a new treatment designed to reduce allergy symptoms by targeting IgE, a protein involved in allergic reactions. After the injection, none of the dogs showed any serious side effects, and two of them had significantly lower levels of IgE in their blood for up to 112 days. This suggests that the treatment could be effective in managing allergies in dogs, similar to a treatment used in humans. Overall, the injection was safe and showed promise in reducing allergy-related immune responses in these dogs.
People also search for: dog allergy treatment · IgE levels in dogs · monoclonal antibody for dog allergies
Abstract
BACKGROUND: The therapeutic monoclonal antibody omalizumab that is specific for IgE has proven to be an effective addition to the treatment of allergic disease in humans. HYPOTHESIS/OBJECTIVES: The aims of this study were to demonstrate the safety and immunomodulating effects of a single injection of a monoclonal antibody single chain variable fragments (scFv) specific for canine IgE in normal dogs. ANIMALS: Three normal dogs were bled for EDTA whole blood samples for 112 days post-injection (dpi). A fourth dog was monitored for 28 days. METHODS: Anti-IgE scFv was pegylated to minimize scFv dimerization. Four normal dogs were injected once subcutaneously with anti-IgE scFv at 1 mg/kg. Flow cytometry was performed on whole blood. Plasma levels of IgE were measured by ELISA. RESULTS: None of the four dogs showed signs of anaphylaxis. All dogs demonstrated decreases in IgE(+) cells in lymphocyte-gated events by 14 dpi. Dogs C and D returned to pre-injection levels by 21 days, whereas dogs A and B remained below pre-injection levels until Day 112. Similar differences were seen in IgE-bearing granulocyte-gated cells. Free plasma IgE decreased below pre-injection levels by 47% in Dog A and by 52% in Dog B at 112 days. Dogs C and D did not change by more than 32% from preinjection levels. CONCLUSION: A single injection of monomeric, pegylated scFv with high affinity for dog IgE was demonstrated to be safe. Marked reduction in IgE-bearing lymphocytes and granulocytes accompanied by reduced "free" plasma IgE level in two of four dogs is analogous to omalizumab in humans.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27426720/